Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan (ESPECIAL)
Primary Purpose
Hypertension, Chronic Kidney Disease, Microalbuminuria
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Intensive education of low salt diet
Sponsored by
About this trial
This is an interventional treatment trial for Hypertension focused on measuring hypertension, Chronic kidney disease, albuminuria, low salt diet, Angiotensin II receptor blocker
Eligibility Criteria
Inclusion Criteria:
- Aged 19 years or more and 75 years or less
- Hypertension patients: Patients whose blood pressure is 140/90mmHg and over, patients is newly diagnosed with hypertension or is prescribed antihypertensive medications.
- Hypertensive patients verified 2 times or more of albuminuria 30 mg/g cr or more in a spot urine sample with interval of 1 week or more in recent 6 months
- Estimated glomerular filtration rate (GFR) by Modification of Diet in Renal Disease (MDRD) equation 30 ml/min/1.73 m2 or more
- Patients who give written consent to this study by oneself
Exclusion Criteria:
- Blood pressure more than 160/100 mmHg
- Pregnant
- Serum potassium level more than 5.5 mEq/L at screening period
- Patients with malignancy, acute cerebral infarction, acute myocardial infarction, unstable angina, percutaneous coronary arterial intervention (PCI), or coronary artery bypass graft (CABG) in recent 6 months
- Patients with diabetes mellitus
- Patients who have an allergy to Olmesartan
- Patients who were involved in other clinical trial in recent 1 month or are participated in screening period
- Patients taking medication(s) of corticosteroid or immunosuppressant in a screening period
Sites / Locations
- Seoul National University Bundang Hospital
- Dongguk University Ilsan Hospital
- Seoul National University Hospital
- Kyung Hee University
- Seoul St. Mary's Hospital
- Konkuk University School of Medicine
- SMG-SNU Boramae Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intensive education of low salt diet
Conventional diet group
Arm Description
For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the "intensity of education")
Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
Outcomes
Primary Outcome Measures
∆Albuminuria by 24-hour Urine Protein Excretion
Change in albuminuria as a 24-hour urine protein excretion by intensive education of low salt diet during taking olmesartan
*In outcome measure data table, the 24-hour urine collection at 16th week was omitted in 3 out of 245 patients (1 for intensive education group and 2 for conventional education group). Values of each study week were "mean" of all participants on specific study week, but "∆albuminuria (week 8 - week 16)" value was "mean" of ∆ values of "8 weeks-16 weeks" in each individuals. Therefore, values of 3 patients were excluded in "mean of ∆albuminuria (week 8 - week 16)". That's why simple subtraction (week 8 - week 16) of values are not matched with the data.
Secondary Outcome Measures
∆Hemoglobin (0 Week - 16 Weeks)
The change of hemoglobin after prescription of Olmesartan
Na Excretion Change in 24 Hour-urine Collection Between Weeks 8 and 16
Change of sodium excretion rate in 24 hour-urine collection by intensive education for low salt diet at week 16
Systolic and Diastolic Blood Pressure Change Between Weeks 8 and 16
Change in Systolic and Diastolic Blood Pressure from Week 8 to Week 16 in the Intensive Education Group compared to the Conventional Education Group
Full Information
NCT ID
NCT01552954
First Posted
February 24, 2012
Last Updated
December 10, 2014
Sponsor
Seoul National University Bundang Hospital
Collaborators
Daiichi Sankyo, Inc., Daewoong Pharmaceutical Co. LTD.
1. Study Identification
Unique Protocol Identification Number
NCT01552954
Brief Title
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Acronym
ESPECIAL
Official Title
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Bundang Hospital
Collaborators
Daiichi Sankyo, Inc., Daewoong Pharmaceutical Co. LTD.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Purpose of this study
Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional prescription of medication.
Intensive education for low salt diet will decrease the amount of 24 hour-urine sodium excretion compared to control group, effectively.
Detailed Description
Background
A. The chronic kidney disease (CKD) is the one of the main burden of chronic diseases and the prevalence of CKD is increasing in worldwide. In Korea, the prevalence of CKD was reported as 13.7% among urban Korean adults in 2008 by our study group.
B. It is well known the CKD is the most important risk factor to cardiovascular events, cardiovascular mortality, all cause-mortality, and hospitalization. The cost of the management for the CKD was high and it took 3.25% of all budgets for medical reimbursement in 2004 for all Koreans, which was ranked on the top of expenditure for single disease category.
C. The most popular risk factors to CKD progression are aging, obesity, hyperlipidemia, diabetes mellitus, hypertension, and proteinuria. The hypertension and proteinuria also cause the cardiovascular events and increase the mortality rate.
D. The inhibitors for renin-angiotensin aldosterone system, angiotensin II type I receptor blocker (ARB) and angiotensin converting enzyme inhibitor (ACEI), are well known medications to prevent cardiovascular events and renal functional deterioration to end stage renal disease(ESRD) in patients with hypertension, non-diabetic CKD, or diabetic nephropathy. One of the adverse events of ARB is the decrease of hemoglobin. Inoue et al reported the level of hemoglobin was decreased in amount of 0.45 ±0.89 g/dL after prescription of ARB and valsartan decreased the erythropoietin in 6 days after medication. The exact mechanism of decrease of hemoglobin by ARB was not fully verified but it is related to decrease effects of angiotensin II on aggravating hypoxia in the kidney and on the activation of hypoxia-inducible factor 1α (HIF1a) and then decrease the production of erythropoietin as in the report of Durmus et al. Considering that the relationships between ARB usage and decrease of proteinuria in transplanted kidney, between aggravation of hypoxia or HIF1a and CKD, and between ARB and the decrease of HIF1a or erythropoietin(EPO), we could postulate that the decrease of hemoglobin would not be a adverse effect of ARB to deteriorate patients' condition but a co-phenomenon of ARB's anti-RAS effect and a marker of ARB's effectiveness.
E. The anti-proteinuric effect of ARB is decreased by high salt intake. For example, ARB treatment without low salt intake decreased proteinuria by 30% in patients with proteinuria 2-10g/day compared to baseline value and addition of low salt diet to ARB treatment further decreased proteinuria up to 25%. But, using slow salt tablets, increase of daily intake of sodium diminished the anti-proteinuric effect of ARB in diabetic nephropathy.
F. The previous studies for the effect of ARB on proteinuria affected by sodium intake took the methods of controlled diet by researcher or using slow salt tablet but these method are not practical to adopt in real clinical practice.
G. The moderate and mild decrease of daily sodium intake which lower the daily excretion of sodium by 55 mEq/day had an effect of decrease of proteinuria by 11% in hypertensive patients.
H. The mean amount of sodium of Korean diets was reported as high as 208 mmol/day in Intersalt study, which is more than 11 g of salt. The recent reports also showed the trend of high salt-intake by Koreans.
Rationale So, It is worth to do this study because
high salt intake is prevalent in Koreans,
high salt diet diminishes the effect of ARB on proteinuria
the methods used in previous studies were not suitable to apply to clinical practice,
and there were no study to reveal the decrease of hemoglobin would the marker for the effect of ARB and not be a adverse event of ARB.
Objectives
Primary objective: The difference between amount of albuminuria after usage of Olmesartan and amount of albuminuria after prescription of Olmesartan with intensive diet education in intervention group is higher than the difference of albuminuria in control group.
Secondary objective:
Item 1: In all patients, Olmesartan decreases the albuminuria. Item 2: In all patients, the change of hemoglobin after prescription of Olmesartan is proportional to the change of albuminuria and serum erythropoietin.
Item 3: Intensive education for low salt diet induces the significant decrease of daily sodium excretion in Intervention group compared to control group.
Item 4: Intensive education for low salt diet induces the significant decrease of blood pressure in Intervention group compared to control group.
Study Flow
Period
Washout period (-8 weeks;Point 0 to 0 weeks; Point 1)
Olmesartan Period ( 0 week; point 1 to 8 weeks; point 2)
Intervention period (8 week ; point 2 to 16 weeks; point 3)
For patients with taking ACEI, other ARB, diuretics, or renin inhibitor, already; Initial wash-out period for 8 weeks, and then (point 1) prescription of Olmesartan 40 mg qd for 8 weeks, and then (point 2) allocation to Intensive group or control group for 8 weeks, and then the study will be over (point 3).
For patients without taking ACEI, other ARB, diuretics, or renin inhibitor; For initial 8 weeks, adjust the blood pressures around 140/90 mmHg, and then (point 1) prescription of Olmesartan 40 mg qd for 8 weeks, and then (point 2) allocation to Intensive group or control group for 8 weeks, and then the study will be over (point 3).
Blood pressure control Adjust the blood pressures around 140/90 mmHg with other hypertensive drugs except ACEI, other ARB, diuretics, or renin inhibitor during whole period.
Intensive diet education:
For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Chronic Kidney Disease, Microalbuminuria
Keywords
hypertension, Chronic kidney disease, albuminuria, low salt diet, Angiotensin II receptor blocker
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
269 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intensive education of low salt diet
Arm Type
Experimental
Arm Description
For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the "intensity of education")
Arm Title
Conventional diet group
Arm Type
No Intervention
Arm Description
Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
Intervention Type
Behavioral
Intervention Name(s)
Intensive education of low salt diet
Other Intervention Name(s)
low salt diet, Angiotensin II converting enzyme, albuminuria, chronic kidney disease
Intervention Description
For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
Primary Outcome Measure Information:
Title
∆Albuminuria by 24-hour Urine Protein Excretion
Description
Change in albuminuria as a 24-hour urine protein excretion by intensive education of low salt diet during taking olmesartan
*In outcome measure data table, the 24-hour urine collection at 16th week was omitted in 3 out of 245 patients (1 for intensive education group and 2 for conventional education group). Values of each study week were "mean" of all participants on specific study week, but "∆albuminuria (week 8 - week 16)" value was "mean" of ∆ values of "8 weeks-16 weeks" in each individuals. Therefore, values of 3 patients were excluded in "mean of ∆albuminuria (week 8 - week 16)". That's why simple subtraction (week 8 - week 16) of values are not matched with the data.
Time Frame
changes from week 8 at week 16 (week 8 - week 16)
Secondary Outcome Measure Information:
Title
∆Hemoglobin (0 Week - 16 Weeks)
Description
The change of hemoglobin after prescription of Olmesartan
Time Frame
0 week, 16 weeks
Title
Na Excretion Change in 24 Hour-urine Collection Between Weeks 8 and 16
Description
Change of sodium excretion rate in 24 hour-urine collection by intensive education for low salt diet at week 16
Time Frame
week 8 and week 16
Title
Systolic and Diastolic Blood Pressure Change Between Weeks 8 and 16
Description
Change in Systolic and Diastolic Blood Pressure from Week 8 to Week 16 in the Intensive Education Group compared to the Conventional Education Group
Time Frame
week 8 and week 16
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged 19 years or more and 75 years or less
Hypertension patients: Patients whose blood pressure is 140/90mmHg and over, patients is newly diagnosed with hypertension or is prescribed antihypertensive medications.
Hypertensive patients verified 2 times or more of albuminuria 30 mg/g cr or more in a spot urine sample with interval of 1 week or more in recent 6 months
Estimated glomerular filtration rate (GFR) by Modification of Diet in Renal Disease (MDRD) equation 30 ml/min/1.73 m2 or more
Patients who give written consent to this study by oneself
Exclusion Criteria:
Blood pressure more than 160/100 mmHg
Pregnant
Serum potassium level more than 5.5 mEq/L at screening period
Patients with malignancy, acute cerebral infarction, acute myocardial infarction, unstable angina, percutaneous coronary arterial intervention (PCI), or coronary artery bypass graft (CABG) in recent 6 months
Patients with diabetes mellitus
Patients who have an allergy to Olmesartan
Patients who were involved in other clinical trial in recent 1 month or are participated in screening period
Patients taking medication(s) of corticosteroid or immunosuppressant in a screening period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ho Jun Chin, PhD
Organizational Affiliation
Seoul National University Bundang Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chun-Soo Lim, PhD
Organizational Affiliation
SMG-SNU Boramae Medical Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Dong Ki Kim, PhD
Organizational Affiliation
Seoul National University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Suhnggwon Kim, PhD
Organizational Affiliation
Seoul National University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bum Soon Choi, PhD
Organizational Affiliation
Seoul St. Mary's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sang-Ho Lee, PhD
Organizational Affiliation
Kyunghee University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jung-Hwan Park, PhD
Organizational Affiliation
Konkuk University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sung Joon Shin, PhD
Organizational Affiliation
DongGuk University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
State/Province
Kyeong ki
ZIP/Postal Code
463787
Country
Korea, Republic of
Facility Name
Dongguk University Ilsan Hospital
City
Ilsan
State/Province
Kyeongki
ZIP/Postal Code
410773
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110744
Country
Korea, Republic of
Facility Name
Kyung Hee University
City
Seoul
ZIP/Postal Code
134727
Country
Korea, Republic of
Facility Name
Seoul St. Mary's Hospital
City
Seoul
ZIP/Postal Code
137701
Country
Korea, Republic of
Facility Name
Konkuk University School of Medicine
City
Seoul
ZIP/Postal Code
143729
Country
Korea, Republic of
Facility Name
SMG-SNU Boramae Medical Center
City
Seoul
ZIP/Postal Code
156707
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
18272844
Citation
Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008 May;19(5):999-1007. doi: 10.1681/ASN.2007060693. Epub 2008 Feb 13.
Results Reference
background
PubMed Identifier
19549737
Citation
Ekinci EI, Thomas G, Thomas D, Johnson C, Macisaac RJ, Houlihan CA, Finch S, Panagiotopoulos S, O'Callaghan C, Jerums G. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care. 2009 Aug;32(8):1398-403. doi: 10.2337/dc08-2297. Epub 2009 Jun 23.
Results Reference
background
PubMed Identifier
19620514
Citation
He FJ, Marciniak M, Visagie E, Markandu ND, Anand V, Dalton RN, MacGregor GA. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension. 2009 Sep;54(3):482-8. doi: 10.1161/HYPERTENSIONAHA.109.133223. Epub 2009 Jul 20.
Results Reference
background
PubMed Identifier
3416162
Citation
Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ. 1988 Jul 30;297(6644):319-28. doi: 10.1136/bmj.297.6644.319.
Results Reference
background
PubMed Identifier
15983240
Citation
Swift PA, Markandu ND, Sagnella GA, He FJ, MacGregor GA. Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension. 2005 Aug;46(2):308-12. doi: 10.1161/01.HYP.0000172662.12480.7f. Epub 2005 Jun 27.
Results Reference
background
PubMed Identifier
34164803
Citation
McMahon EJ, Campbell KL, Bauer JD, Mudge DW, Kelly JT. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2021 Jun 24;6(6):CD010070. doi: 10.1002/14651858.CD010070.pub3.
Results Reference
derived
PubMed Identifier
33782940
Citation
Conley MM, McFarlane CM, Johnson DW, Kelly JT, Campbell KL, MacLaughlin HL. Interventions for weight loss in people with chronic kidney disease who are overweight or obese. Cochrane Database Syst Rev. 2021 Mar 30;3(3):CD013119. doi: 10.1002/14651858.CD013119.pub2.
Results Reference
derived
PubMed Identifier
26098847
Citation
An JN, Hwang JH, Lee JP, Chin HJ, Kim S, Kim DK, Kim S, Park JH, Shin SJ, Lee SH, Choi BS, Lim CS. The Decrement of Hemoglobin Concentration with Angiotensin II Receptor Blocker Treatment Is Correlated with the Reduction of Albuminuria in Non-Diabetic Hypertensive Patients: Post-Hoc Analysis of ESPECIAL Trial. PLoS One. 2015 Jun 22;10(6):e0128632. doi: 10.1371/journal.pone.0128632. eCollection 2015.
Results Reference
derived
PubMed Identifier
25531146
Citation
Baek SH, Kim S, Kim DK, Park JH, Shin SJ, Lee SH, Choi BS, Chin HJ, Kim S, Lim CS. A low-salt diet increases the estimated net endogenous acid production in nondiabetic chronic kidney disease patients treated with angiotensin receptor blockade. Nephron Clin Pract. 2014;128(3-4):407-13. doi: 10.1159/000369558. Epub 2014 Dec 18.
Results Reference
derived
Learn more about this trial
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
We'll reach out to this number within 24 hrs